sb 203580 has been researched along with 5-nitro-2-(3-phenylpropylamino)benzoic acid in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (5-nitro-2-(3-phenylpropylamino)benzoic acid) | Trials (5-nitro-2-(3-phenylpropylamino)benzoic acid) | Recent Studies (post-2010) (5-nitro-2-(3-phenylpropylamino)benzoic acid) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 561 | 0 | 90 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Belsey, MJ; Davies, AR; Kozlowski, RZ; Witchel, HJ | 1 |
1 other study(ies) available for sb 203580 and 5-nitro-2-(3-phenylpropylamino)benzoic acid
Article | Year |
---|---|
Inhibition of ERK and JNK decreases both osmosensitive taurine release and cell proliferation in glioma cells.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Anthracenes; Apoptosis; Astrocytoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dicumarol; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Imidazoles; Ion Channels; JNK Mitogen-Activated Protein Kinases; Necrosis; Niflumic Acid; Nitrobenzoates; Osmolar Concentration; Pyridines; Rats; Taurine | 2007 |